Author(s):
Afonso, Julieta Alexandra Pereira ; Freitas, R. ; Lobo, F. ; Morais, A. ; Amaro, T. ; Reis, R. M. ; Baltazar, Fátima ; Longatto Filho, Adhemar ; Santos, L. ; Oliveira, J.
Date: 2015
Persistent ID: https://hdl.handle.net/1822/40240
Origin: RepositóriUM - Universidade do Minho
Subject(s): Urothelial bladder carcinoma; Biomarkers; Neovascularization; Metastasis suppressors; Tumour metabolism; Carcinoma urotelial da bexiga; Biomarcadores; Neovascularização; Moléculas supressoras de metástases; Metabolismo tumoral
Description
Urothelial bladder carcinoma (UBC), the most frequent type (90%) of bladder cancer and the second most common malignancy of the urogenital region, is a relatively well understood type of cancer, with numerous studies concerning pathogenetic pathways, natural history and bladder tumor biology being reported. Despite this, it continues to remain a challenge in the oncology field, mostly due to its relapsing and progressive nature, and to the heterogeneity in the response to cisplatin-containing regimens. Although the formulae based on clinical staging and histopathological parameters are classically used as diagnostic and prognostic tools, they have proven insufficient to characterize the individual biological features and clinical behaviour of the tumours. Understanding the pathobiology of the disease can add important information to these classical criteria, and contribute to accurately predict outcome and individualize therapy for UBC patients. In this line of investigation, we found that tumour angiogenesis and lymphangiogenesis, the process of invasion and metastasis and the energy metabolism reprogramming/tumour microenvironment encompass several potential biomarkers that seem to infl bladder cancer aggressiveness and chemoresistance. We particularly highlight the roles of lymphovascular invasion, and of RKIP, CD147 and MCT1 immunoexpressions, as relevant prognostic and/or predictive biomarkers, and as promising areas of therapeutic intervention, eliciting for the development of additional studies that can validate and further explore these biomarkers.
